22nd Feb 2017 13:58
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R G Connor | |||
b) | Position/status | President, Global Manufacturing & Supply | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £0.0000 | 13,284 (Deferred) |
| ||
| £0.0000 | 4,428 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information |
| |||
Aggregated volume Price | 17,712 £0.0000 | ||||
e) | Date of the transaction | 2017-02-21 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R G Connor | |||
b) | Position/status | President, Global Manufacturing & Supply | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.3575 | 6,369 (Deferred) |
| ||
| £16.3575 | 2,124 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information |
| |||
Aggregated volume Price | 8,493 £16.3575 | ||||
e) | Date of the transaction | 2017-02-21 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr S A Hussain | |||
b) | Position/status | President, Global Pharmaceuticals | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £0.0000 | 9,743 (Deferred) |
| ||
| £0.0000 | 3,248 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information |
| |||
Aggregated volume Price | 12,991 £0.0000 | ||||
e) | Date of the transaction | 2017-02-21 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr S A Hussain | |||
b) | Position/status | President, Global Pharmaceuticals | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.4650 | 4,234 (Deferred) |
| ||
| £16.4750 | 1,412 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information |
| |||
Aggregated volume Price | 5,646 £16.4675 | ||||
e) | Date of the transaction | 2017-02-21 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr P J T Vallance | |||
b) | Position/status | President, R&D | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The exercise of nil-cost options over Ordinary Shares granted on 12 February 2014 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £0.0000 | 26,863 (Deferred) |
| ||
| £0.0000 | 8,954 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information |
| |||
Aggregated volume Price | 35,817 £0.0000 | ||||
e) | Date of the transaction | 2017-02-21 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr P J T Vallance | |||
b) | Position/status | President, R&D | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 21 February 2017 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £16.3575 | 12,879 (Deferred) |
| ||
| £16.3575 | 4,294 (Matching) |
| ||
|
|
|
| ||
d) | Aggregated information |
| |||
Aggregated volume Price | 17,173 £16.3575 | ||||
e) | Date of the transaction | 2017-02-21 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
Related Shares:
Glaxosmithkline